PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.

"Declarations Ethics approval and consent to participateOrganoids and human FFPE tissues were obtained within the BarretNET registry, which was approved by the ethics committee of the Technical University Hospital of Munich (#5291/12). All animal experiments were performed following protocols approved by the Regierung von Oberbayern (ROB 55.2–2532.Vet_02-15–29, Vet_02-20–69, and Vet_02-16–24) according to the German Animal Welfare Act and Ethical Guidelines of the Klinikum rechts der Isar, Technical University of Munich (TUM). Consent for publicationN/A. Competing interestsS.K. is a shareholder of Summit Biomedical Imaging, LLC. SK is a co- inventor on PCT application WO2016164771. V.N. is a founder and equity owner of sThesis GmbH, iThera Medical GmbH, Spear UG and I3 Inc. All other authors have no relevant conflict of interest to declare. Competing interests S.K. is a shareholder of Summit Biomedical Imaging, LLC. SK is a co- inventor on PCT application WO2016164771. V.N. is a founder and equity owner of sThesis GmbH, iThera Medical GmbH, Spear UG and I3 Inc. All other authors have no relevant conflict of interest to declare."

"Funding Open Access funding enabled and organized by Projekt DEAL. The present study was supported by the Deutsche Forschungsgemeinschaft (DFG) SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies B05 (Project Number 68647618)."